Morgan Stanley Reduces Stake in Tenax Therapeutics (TENX) Below 5% Threshold

On April 8, 2026, Morgan Stanley filed an amended Schedule 13G (Amendment No. 1) regarding its holdings in Tenax Therapeutics, Inc. (TENX). The filing indicates that as of the event date on March 31, 2026, Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have ceased to be beneficial owners of more than five percent of the company's common stock. Morgan Stanley reported a beneficial ownership of 596,564 shares, representing a 3.5% stake in the company. This is a decrease from its previously reported position. Within the total shares, Morgan Stanley Capital Services LLC specifically holds 583,297 shares, accounting for 3.4% of the class. The securities were acquired in the ordinary course of business and were not held for the purpose of influencing or changing control of the issuer. The filing was executed as a joint statement by Morgan Stanley and Morgan Stanley Capital Services LLC, both Delaware-based entities operating out of New York.